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症 例 報 告（第２２回若手奨励賞受賞論文）
EGFR 遺伝子変異陽性非小細胞肺癌の再発に対してニボルマブが有効で
あった一例
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四国医誌 ７５巻５，６号 ２３３～２３８ DECEMBER２５，２０１９（令元） ２３３
胸部 X 線（図１）：両側肋横骨は鋭角で胸水なし。右上
肺野に３×２cm 大の腫瘤影を認める。





















WBC ５，９００／μL CRP ０．０mg/dl CEA １４．６ng/mL
Neut ４７．９％ AST １５U/L SLX ２６．０U/mL
Eo １．０％ ALT １３U/L KL‐６ １６３ U/mL
Baso ０．２％ ALP １９３U/L シフラ １．７ng/mL
Mono ８．８％ LD １６２U/L PRO-GRP ５０．９ng/mL
Lymp ４２．１％ BUN １２．９mg/dL T-SPOT （－）
RBC ４０８×１０４/μL CRE ０．７６mg/dL アスペルギルス抗原 ０．７
Hb １３．４g/dL Na １４５．１mg/dL C-ANCA １．０未満





























変異を含めた uncommon mutation では common muta-
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陽性非小細胞肺癌で T７９０M 陰性の患者における EGFR-
TKI 治療後のニボルマブに感受性がある症例は，CD８陽


















L８６１Q の uncommon mutation を有する患者でニボルマ
ブの奏効を経験した。本症例のような臨床報告が増え，
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A case of recurrent EGFR-mutant Non-Small Cell Lung Cancer successfully treated
with Nivolumab
Shoko Yamamoto１）, Ryoko Suzue２）, Kenya Miyamoto２）, Toshifumi Tezuka２）, Mami Inayama２）, and
Takashi Haku２）
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SUMMARY
Nivolumab is approved for the treatment of patients with advanced non-small cell lung cancer
（NSCLC）who experience progression of disease on or after standard platinum-based chemotherapy.
But there are still a few reports of nivolumab treatment in after EGFR-TKI treatment since NSCLC
patients with EGFR mutations has been said to have poor effect on anti-PD-１/PD-L１agents. Also,
there are several reports of severe interstitial pneumonitis when Nivolumab is used after EGFR-
TKI treatment.
A８８‐year‐old woman was diagnosed with lung adenocarcinoma with an EGFR exon２１L８６１Q
mutation（clinical stage ⅢA ; cT４N０M０）. She had received Gefitinib for１８months, until she had
disease progression（PD）. Re-biopsy showed T７９０M-negative, ALK-negative and PD-L１０%. Seve-
ral other drugs were attempted after Gefitinib, but none of them showed any effect. Nivolumab
treatment was initiated as her sixth chemotherapy, four and a half years after being diagnosed.
Her tumor responded well to Nivolumab treatment and still remains effective without any severe
side effects such as interstitial pneumonitis.
Our case suggests that Nivolumab treatment is a treatment option for NSCLC patients with
EGFR uncommon mutations who are refractory to EGFR-TKI treatment.
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